AbbVie Inc (4AB)

91.55
-0.40(-0.44%)
  • Volume:
    66
  • Bid/Ask:
    91.13/91.58
  • Day's Range:
    91.25 - 91.90
  • Type:Equity
  • Market:Germany
  • ISIN:US00287Y1091
  • WKN:A1J84E

4AB Overview

Prev. Close
91.95
Day's Range
91.25-91.9
Revenue
-
Open
91.25
52 wk Range
68.08-102.94
EPS
-
Volume
66
Market Cap
162B
Dividend (Yield)
4.40
(4.78%)
Average Vol. (3m)
504
P/E Ratio
29.34
Beta
-
1-Year Change
20.97%
Shares Outstanding
1,767,175,532
Next Earnings Date
-
What is your sentiment on AbbVie Inc?
or
Market is currently closed. Voting is open during market hours.

AbbVie Inc News

AbbVie Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellBuy
Technical IndicatorsSellSellStrong BuyStrong SellStrong Buy
SummarySellSellNeutralStrong SellStrong Buy

AbbVie Inc Company Profile

AbbVie Inc Company Profile

Employees
48000

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Read More
  • markets dropping due to correcting. taking stocks in general with them. I'm sure once markets start on am upward 👆 abbv will follow suit the pharma warning on boxes are a short term concern. .....
    0
    • 32 PE ratio is to high
      13
      • it's, but is the world we live in now
        0
      • The P/E is about 9, you are talking about forward P/E
        0
      • Yeah, current P/E is about 8-9
        0
    • AbbVie sinks 5% to a session low after the U.S. Food and Drug Administration said the drug makers arthritis medicine, Rinvoq, and Pfizer’s Xeljanz, will need a new boxed warning, the agency’s most prominent caution, pointing to an increased risk of death.
      7
      • Thank you for the information. RESPECT 🤝
        0
      • ...and Pfizer, -0,5%
        0
      • That is true, however, that medicine in particular represents only 3% of abbvie's total revenue as far as i could investigate... the market is totally overreacting to the news in my opinion
        0
    • AbbVie Shares Move Lower On Increased Volume, Down ~10%, Seeing Interest In Put Option Sweeps On BZ Signals(Benzinga)
      0
      • Wham am i missing? Bought some more but looks like someone big is selling
        0
        • No idea.. should I buy? No news either.
          0
      • What happen?
        0
        • No idea, nothing in the news.
          0
        • someone sold I guess, I bought some more
          0
        • Big time put options at 110 today. Some big money moved it down. I guess were just avg investors in a billionaires world. Oh well , ill add. Ive been holding this stock since 50$. Nice dividend.
          0
      • Don't miss this next step.
        0
        • Dividends Time. Yea!
          0
          • Yep no guidance
            0
            • Probsbly dump today
              2
              • let's breakthrough resistance of 118 and move on up.
                0
                • let's get thru 115 and move on. I look forward to the 120 mark.
                  0
                  • May be the best pharma look forward to 150
                    0
                    • Love this company. Found Friday a good day to add for multiple reasons. https://antwckiss.com/blog/abbvie-stock-buying-opportunity/
                      0
                      • ima save up to buy a full share. and hold it :) will we see 200$????
                        0
                        • This is definitely a buy! Looking forward to break all time new high soon.
                          0
                          • it did today. Abbv is hot stuff
                            0
                        • best stock ever
                          0
                          • Dividends locked in! Now let's see price move.
                            0
                            • Very bullish if this is up 1-1.5% after dividends paid.
                              0
                          • I’m about to run out of money buying this, keep dropping.
                            1
                            • The FDA extending the review of too many of their drugs.
                              0
                            • go for it
                              0
                            • Elain DurhamDoesnt matter a while lot considering their forward P/E is in the 8 range. Sign me up.
                              0
                          • can't help but think buying now could realize a fast return of 10+ bucks per share, plus the nice dividends.
                            1
                            • got it now keep it up.
                              0
                          • Thank you weak hands!
                            0
                            • Buy now if you can.
                              0
                              • added more on this dip. A bit of delay in the FDA review should not trigger this silly sell of.
                                0
                                • yeong cha!  yeong cha!!!
                                  0
                                  • still, great dividend stock
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.